Nuveen Asset Management Portfolio holdings
Nuveen Asset Management, founded in 1898 by John Nuveen and headquartered in Chicago, Illinois, is a leading global investment manager and subsidiary of TIAA, overseeing hundreds of billions in assets with a focus on fixed income, equities, and sustainable investing. Initially known for municipal bonds, Nuveen has expanded into a broad range of strategies, including mutual funds, ETFs, closed-end funds, and private capital solutions, serving institutional investors, financial advisors, and individuals. The firm emphasizes income-generating investments and ESG (environmental, social, governance) integration, leveraging its deep research capabilities and a century-long legacy in the bond market. With a strong presence in North America and growing international reach, Nuveen blends tradition with innovation to meet diverse client needs in the evolving investment landscape.
Top Buys
| 1 |
Advanced Micro Devices
AMD
|
$922M |
| 2 |
EOG Resources
EOG
|
$517M |
| 3 |
Mastercard
MA
|
$436M |
| 4 |
Las Vegas Sands
LVS
|
$385M |
| 5 |
Booking.com
BKNG
|
$382M |
Top Sells
| 1 |
Qualcomm
QCOM
|
$660M |
| 2 |
Morgan Stanley
MS
|
$519M |
| 3 |
PayPal
PYPL
|
$479M |
| 4 |
Meta Platforms (Facebook)
META
|
$478M |
| 5 |
Pfizer
PFE
|
$405M |
Sector Composition
| 1 | Technology | 24.82% |
| 2 | Financials | 12.45% |
| 3 | Healthcare | 12.44% |
| 4 | Consumer Discretionary | 11.85% |
| 5 | Industrials | 8.4% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
3026
Spyre Therapeutics
SYRE
$1.03B
| $425K | ﹤0.01% |
6,765
+12
| +0.2% | +$754 |
|
|
PRTK
3027
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $425K | ﹤0.01% |
133,751
+1,002
| +0.8% | +$3.18K |
|
3028
NN Inc
NNBR
$125M
| $422K | ﹤0.01% |
146,966
-33,721
| -19% | -$96.8K |
|
3029
Vor Biopharma
VOR
$248M
| $422K | ﹤0.01% |
55,296
+1,048
| +2% | +$8K |
|
3030
Cytosorbents Corp
CTSO
$60.6M
| $420K | ﹤0.01% |
135,134
+1,137
| +0.8% | +$3.53K |
|
|
IGMS
3031
DELISTED
IGM Biosciences
IGMS
| $420K | ﹤0.01% |
26,412
+2,530
| +11% | +$40.2K |
|
3032
TherapeuticsMD
TXMD
$12.5M
| $419K | ﹤0.01% |
21,234
| – | – |
|
|
MILE
3033
DELISTED
Metromile, Inc. Common Stock
MILE
| $417K | ﹤0.01% |
338,963
+122,600
| +57% | +$151K |
|
3034
ClearPoint Neuro
CLPT
$314M
| $416K | ﹤0.01% |
44,545
| – | – |
|
|
LBC
3035
DELISTED
Luther Burbank Corporation Common Stock
LBC
| $414K | ﹤0.01% |
30,683
+343
| +1% | +$4.63K |
|
3036
Energy Transfer Partners
ET
$59.7B
| $408K | ﹤0.01% |
41,200
-786
| -2% | -$7.78K |
|
3037
Zevia
ZVIA
$193M
| $402K | ﹤0.01% |
99,199
+88,542
| +831% | +$359K |
|
|
ATHX
3038
DELISTED
Athersys, Inc. Common Stock
ATHX
| $395K | ﹤0.01% |
22,274
+149
| +0.7% | +$2.64K |
|
3039
Janux Therapeutics
JANX
$1.44B
| $392K | ﹤0.01% |
25,660
+6,203
| +32% | +$94.8K |
|
3040
Day One Biopharmaceuticals
DAWN
$773M
| $391K | ﹤0.01% |
39,774
+24,813
| +166% | +$244K |
|
3041
Global Water Resources
GWRS
$269M
| $388K | ﹤0.01% |
24,245
| – | – |
|
3042
Zynex
ZYXI
$45.1M
| $387K | ﹤0.01% |
67,003
+521
| +0.8% | +$3.01K |
|
3043
Humacyte
HUMA
$226M
| $382K | ﹤0.01% |
+60,587
| New | +$382K |
|
3044
Tarsus Pharmaceuticals
TARS
$2.43B
| $381K | ﹤0.01% |
21,763
| – | – |
|
3045
SAP
SAP
$313B
| $378K | ﹤0.01% |
3,409
-66,196
| -95% | -$7.34M |
|
|
ME
3046
DELISTED
23andMe Holding Co. Class A Common Stock
ME
| $377K | ﹤0.01% |
+5,272
| New | +$377K |
|
|
DOYU
3047
DouYu International Holdings
DOYU
$234M
| $375K | ﹤0.01% |
18,012
-108,500
| -86% | -$2.26M |
|
|
TEAD
3048
Teads Holding Co. Common Stock
TEAD
$155M
| $375K | ﹤0.01% |
+33,575
| New | +$375K |
|
|
LENZ
3049
LENZ Therapeutics
LENZ
$1.2B
| $373K | ﹤0.01% |
7,744
+4,380
| +130% | +$211K |
|
|
SQZ
3050
DELISTED
SQZ Biotechnologies Company
SQZ
| $370K | ﹤0.01% |
77,754
+1,347
| +2% | +$6.41K |
|